(2S,5R)-2-CARBAMOYL-3-METHYL-7-OXO-1,6-DIAZABICYCLO(3.2.1)OCT-3-EN-6-YL SULFATE
Mycobacterium Abscessus Pulmonary Disease
The University of QueenslandSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
19 Active assets in the Mycobacterium Abscessus Pulmonary Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Clofazimine The University of Queensland | Phase 2 | CCC |
Trimethoprim The University of Queensland | Phase 2 | CCC |
CEFOXITIN The University of Queensland | Phase 2 | CCC |
Amikacin The University of Queensland | Phase 2 | CCC |
Linezolid The University of Queensland | Phase 2 | CCC |
View all 19 →
Same molecule, other indications
(2S,5R)-2-CARBAMOYL-3-METHYL-7-OXO-1,6-DIAZABICYCLO(3.2.1)OCT-3-EN-6-YL SULFATE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →